

Ellen M Ginzler

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5892321/publications.pdf>

Version: 2024-02-01

58
papers

6,963
citations

159358

30
h-index

182168

51
g-index

58
all docs

58
docs citations

58
times ranked

4112
citing authors

#	ARTICLE	IF	CITATIONS
1	A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2011, 63, 3918-3930.	6.7	1,277
2	Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis. <i>New England Journal of Medicine</i> , 2005, 353, 2219-2228.	13.9	991
3	A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2009, 61, 1168-1178.	6.7	515
4	Novel evidence-based systemic lupus erythematosus responder index. <i>Arthritis and Rheumatism</i> , 2009, 61, 1143-1151.	6.7	397
5	Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1706-1713.	0.5	391
6	The frequency and outcome of lupus nephritis: results from an international inception cohort study. <i>Rheumatology</i> , 2016, 55, 252-262.	0.9	370
7	A multicenter study of outcome in systemic lupus erythematosus. ii.. <i>Arthritis and Rheumatism</i> , 1982, 25, 612-617.	6.7	334
8	A multicenter study of outcome in systemic lupus erythematosus.. <i>Arthritis and Rheumatism</i> , 1982, 25, 601-611.	6.7	320
9	Computer analysis of factors influencing frequency of infection in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1978, 21, 37-44.	6.7	264
10	Low plasma androgens in women with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1987, 30, 241-248.	6.7	262
11	Ataccept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial. <i>Arthritis Research and Therapy</i> , 2012, 14, R33.	1.6	245
12	Disease Control and Safety of Belimumab Plus Standard Therapy Over 7 Years in Patients with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2014, 41, 300-309.	1.0	149
13	Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: Findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial. <i>Arthritis and Rheumatism</i> , 2010, 62, 211-221.	6.7	139
14	Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2012, 64, 3364-3373.	6.7	100
15	Long-term maintenance therapy with azathioprine in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1975, 18, 27-34.	6.7	99
16	Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , 2015, 67, 1837-1847.	2.9	98
17	Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2019, 71, 1125-1134.	2.9	74
18	Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1530-1536.	0.5	70

#	ARTICLE	IF	CITATIONS
19	Antinuclear Antibodyâ€“Negative Systemic Lupus Erythematosus in an International Inception Cohort. <i>Arthritis Care and Research</i> , 2019, 71, 893-902.	1.5	70
20	Lupus community panel proposals for optimising clinical trials: 2018. <i>Lupus Science and Medicine</i> , 2018, 5, e000258.	1.1	62
21	Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis Care and Research</i> , 2018, 70, 1478-1487.	1.5	55
22	Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , 2019, 71, 281-289.	2.9	55
23	Treatment of systemic lupus erythematosus patients with the BAFF antagonist â€œceptibodyâ€•blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials. <i>Arthritis Research and Therapy</i> , 2015, 17, 215.	1.6	48
24	Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 370-378.	0.5	42
25	Prednisone and azathioprine compared to prednisone plus low-dose azathioprine and cyclophosphamide in the treatment of diffuse lupus nephritis. <i>Arthritis and Rheumatism</i> , 1976, 19, 693-699.	6.7	41
26	Systemic Lupus Erythematosus in the Older Age Group: Computer Analysis. <i>Journal of the American Geriatrics Society</i> , 1979, 27, 58-61.	1.3	40
27	A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach. <i>Arthritis and Rheumatology</i> , 2016, 68, 1932-1944.	2.9	40
28	Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 356-362.	0.5	40
29	Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , 2020, 72, 67-77.	2.9	39
30	The clinical significance of raynaud's phenomenon in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1979, 22, 815-819.	6.7	38
31	Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort. <i>Rheumatology</i> , 2018, 57, 677-687.	0.9	37
32	Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies. <i>Lupus Science and Medicine</i> , 2021, 8, e000590.	1.1	31
33	Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. <i>Journal of Autoimmunity</i> , 2020, 106, 102340.	3.0	27
34	Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index. <i>Arthritis and Rheumatology</i> , 2020, 72, 658-666.	2.9	26
35	Evaluating the Properties of a Frailty Index and Its Association With Mortality Risk Among Patients With Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2019, 71, 1297-1307.	2.9	25
36	Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach. <i>Arthritis Care and Research</i> , 2020, 72, 1800-1808.	1.5	23

#	ARTICLE	IF	CITATIONS
37	Comparison of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Systemic Lupus Erythematosus Classification Criteria With Two Sets of Earlier Systemic Lupus Erythematosus Classification Criteria. <i>Arthritis Care and Research</i> , 2021, 73, 1231-1235.	1.5	22
38	Economic Evaluation of Lupus Nephritis in the Systemic Lupus International Collaborating Clinics Inception Cohort Using a Multistate Model Approach. <i>Arthritis Care and Research</i> , 2018, 70, 1294-1302.	1.5	21
39	Accrual of Atherosclerotic Vascular Events in a Multicenter Inception Systemic Lupus Erythematosus Cohort. <i>Arthritis and Rheumatology</i> , 2020, 72, 1734-1740.	2.9	17
40	Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1010-1012.	0.5	12
41	Prediction of hospitalizations in systemic lupus erythematosus using the Systemic Lupus International Collaborating Clinics Frailty Index (SLICCâ€FI). <i>Arthritis Care and Research</i> , 2020, , .	1.5	9
42	Longitudinal analysis of ANA in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1143-1150.	0.5	9
43	Systemic lupus erythematosus trials: successes and issues. <i>Current Opinion in Rheumatology</i> , 2004, 16, 499-504.	2.0	8
44	Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen. <i>Rheumatology</i> , 2019, 58, 1259-1267.	0.9	8
45	Neuropsychiatric Events in Systemic Lupus Erythematosus: Predictors of Occurrence and Resolution in a Longitudinal Analysis of an International Inception Cohort. <i>Arthritis and Rheumatology</i> , 2021, 73, 2293-2302.	2.9	7
46	Clinical trials in lupus nephritis. <i>Current Rheumatology Reports</i> , 2001, 3, 199-204.	2.1	5
47	Management of lupus nephritisâ€”new guidelines revealed. <i>Nature Reviews Rheumatology</i> , 2012, 8, 565-566.	3.5	3
48	Disseminated nocardiosis in an immunosuppressed patient with systemic lupus erythematosus and neuromyelitis optica spectrum disorder. <i>Lupus</i> , 2021, 30, 347-351.	0.8	3
49	Anti-beta 2 glycoprotein I IgA in the SLICC classification criteria dataset. <i>Lupus</i> , 2021, 30, 096120332110142.	0.8	3
50	Effect of Frentizole on Mitogen-Induced Blastogenesis in Human Lymphocytes. <i>Immunopharmacology and Immunotoxicology</i> , 1979, 1, 483-495.	0.8	1
51	Systemic Lupus Erythematosus. <i>Rheumatic Disease Clinics of North America</i> , 2014, 40, xiii-xiv.	0.8	1
52	Preface. <i>Rheumatic Disease Clinics of North America</i> , 2010, 36, xiii.	0.8	0
53	CS-07â€…Economic evaluation of damage accrual in an international SLE inception cohort. , 2018, , .		0
54	Dialogue: commentary on â€”Engaging African-ancestry participants in systemic lupus erythematosus clinic trialsâ€™. <i>Lupus Science and Medicine</i> , 2018, 5, e000306.	1.1	0

#	ARTICLE	IF	CITATIONS
55	1124...Economic evaluation of neuropsychiatric (NP) lupus in an international inception cohort using a multistate model approach. , 2021, , .		0
56	1107...Economic evaluation of hydroxychloroquine use in an international inception cohort. , 2021, , .		0
57	801...Factors associated with SLE flares after HCQ taper, discontinuation or maintenance in the SLICC inception cohort: lower education linked with higher flare risk. , 2021, , .		0
58	1704...Identifying clusters of longitudinal autoantibody profiles associated with systemic lupus erythematosus disease outcomes. , 2021, , .		0